Globe News Wire
28 May 2026, 05:15 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/28/3302503/0/de/basilea-erh%c3%a4lt-weitere-usd-13-mio-von-barda-zur-entwicklung-des-neuartigen-antibiotikums-ceftibuten-ledaborbactam.html
Read source
Search tags
Story key points
3 claims · impact-rated
Basilea may receive up to USD 133 million in additional non-dilutive funding from BARDA for the development of Ceftibuten-Ledaborbactam. — Significant potential for non-dilutive capital reduces financial risk and supports long-term R&D without shareholder dilution.
+0.60Basilea received an additional USD 13.3 million in funding from BARDA to further develop Ceftibuten-Ledaborbactam, including preparations for a Phase 3 clinical program. — Immediate capital injection and progress toward the critical Phase 3 stage validate the candidate's potential.
+0.40Ceftibuten-Ledaborbactam has been granted FDA Qualified Infectious Disease Product (QIDP) and Fast-Track status. — These designations accelerate the regulatory pathway to market and provide potential exclusivity incentives.
+0.30Ticker attribution
Model heads
The company received additional non-dilutive funding from BARDA to develop a novel antibiotic and is preparing for a Phase-3 program.
No ticker relationship head found.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
